Topic: chronic lymphocytic leukemia
ArQule, originally looking for a co-development deal for BTK inhibitor ARQ 531, found itself in a quick-rolling buyout negotiation with Merck.
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.
AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.
Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.
Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.
To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.
J&J enlisted British celebrity home stylist Laurence Llewelyn-Bowen to raise awareness of blood cancer and its symptoms this month.
AstraZeneca’s Calquence has been battling it out in MCL, but the company has had its eye on CLL. And that’s where it’s scored its latest win.
In May, AbbVie and Roche scored an approval for Venclexta and Gazyva in CLL. Tuesday, they rolled out the data that helped get them there.